left-arrow right-arrow pinterest facebook google_plus linkedin

Alliance A041701


Recruiting | Phase II/III

Official Title:

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Study Purpose:

To compare the usual treatment alone to using uproleselan plus the usual treatment.


  • Group 1: Daunorubicin + Cytarabine (usual approach group)
  • Group 2: Daunorubicin + Cytarabine + Uproleselan (study drug)

Patients will either get the usual treatment or the usual treatment plus the study drug for up to 5 months. After treatment is finished the doctor will continue to follow up and watch for side effects for up to 5 years.

Key Participation Requirements:


Male or Female


60 years and older


Acute Myeloid Leukemia


No prior chemotherapy for MDS or AML

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Alliance A041701

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!